The Laser That Replaces a Surgeon's Stitch

TL;DR

• What happened: A Dutch team published the first prospective clinical trial of a sutureless, laser-assisted coronary bypass connector. The ELANA system replaces hand-sewing with a six-step laser technique that keeps the artery open during surgery.
• The numbers: 2.9% device-related major adverse cardiac events at one year (p = 0.0033 vs. historical benchmark). 92.5% of bypasses remained open at six months; 97.5% with the latest-generation catheter.
• Why it matters: The hardest step in bypass surgery — sewing a 2 mm artery to another 2 mm artery on a beating heart — has just been standardised. This is the bottleneck that has kept minimally invasive bypass surgery at roughly 10% of procedures for 25 years.
• What it isn't: This is not a product launch. The device is investigational — no CE mark, no FDA clearance. It's a 71-patient, single-arm trial. The real story is the proof of principle, not the commercial timeline.
• The non-obvious angle: The technology was originally developed for brain surgery and has been used in over 1,000 neurosurgery patients since 2008. The cardiac application is the spin-off, not the original.

What Happened

On 16 July 2026, the Journal of Thoracic and Cardiovascular Surgery — the flagship journal of the American Association for Thoracic Surgery — published the one-year results of the SAFE-CAB II trial. [1]

The study tested a device called the ELANA Anastomotic System, made by a Dutch clinical-stage company called AMT Medical. ELANA stands for Excimer Laser-Assisted Non-occlusive Anastomosis. The name is a mouthful. The idea is not: instead of a surgeon hand-sewing a bypass graft to a coronary artery — a manoeuvre that requires stopping blood flow, working on a vessel roughly 2 millimetres wide, and getting every stitch exactly right — the ELANA system uses a ring-shaped laser catheter to punch a precise hole in the artery wall while blood keeps flowing through it.

The trial enrolled 71 patients at St. Antonius Hospital in Nieuwegein, the Netherlands, with collaboration from Deutsches Herzzentrum der Charité in Berlin. Average age: 71. Average number of bypasses per patient: 3.5. The ELANA was used only for the most clinically important connection — the left internal thoracic artery to the left anterior descending coronary artery (LITA-to-LAD). All other bypasses were hand-sewn as usual.

The trial was monitored by an independent contract research organisation (HEMEX AG), overseen by an independent Data Safety Monitoring Board, and all angiographic data were independently reviewed by Cardialysis in Rotterdam, one of the leading academic core labs in cardiovascular research. [1]

What the Numbers Actually Say

The primary endpoint was device-related major adverse cardiac events (MACE) at one year: cardiac death, heart attack in the LAD territory, or repeat revascularisation of the LAD.

It hit 2.9%. The pre-specified non-inferiority threshold was met with p = 0.0033, benchmarked against the C-Port device's historical 95.24% freedom from MACE. [1]

Six-month patency — whether the bypass was still open — was assessed by coronary angiography:

• 92.5% across the full study
• 97.5% in the subgroup treated with the latest-generation laser catheter

That 97.5% figure matters. It matches the upper range of what the best hand-sewn bypasses achieve. And it came from a device iteration, not from selecting better surgeons.

Overall one-year MACE (including events from the hand-sewn bypasses) was 8.7%, which is consistent with standard CABG outcomes in this patient population. The independent Data Safety Monitoring Board identified no safety concerns. [1]

A companion technique paper published in the Journal of Visualized Surgery in January 2026 described the procedure as a defined six-step technique. In the case described, the ELANA-assisted anastomosis was completed in 20 minutes, contributing to a total operative time of 185 minutes. [2]

What It Actually Means

Coronary artery bypass grafting is one of the most common major surgeries on the planet — roughly 365,000 to 800,000 procedures annually, depending on which estimate you use. [3] [4] It saves lives. It also splits your sternum in half.

For 25 years, surgeons have known there's a better way. Minimally invasive direct coronary artery bypass (MIDCAB) goes through a small incision between the ribs instead of cracking the chest. Robotic-assisted versions exist. Totally endoscopic versions exist. The outcomes are excellent — graft patency matches or exceeds open surgery, recovery is faster, wound infections plummet, and patients go home sooner.

And yet MIDCAB has been stuck at roughly 10% of CABG volume for 15 years. [5]

Why? Because sewing a graft to a coronary artery through a 3–4 cm hole between the ribs, on a beating heart, without the exposure a sternotomy provides, is extraordinarily difficult. It requires "advanced surgical skills," as one review put it. [6] The learning curve is steep — proficiency emerges around 10–50 cases, mastery requires hundreds. Most cardiac surgeons never climb it.

The ELANA system attacks that bottleneck directly. If connecting the artery is the hardest step, and you can make that step standardised, reproducible, and independent of the surgeon's hand-sewing dexterity on any given Tuesday, you change the adoption equation for minimally invasive bypass.

This is not a marginal improvement in surgical technique. It's a platform play. The same principle — laser-assisted, non-occlusive anastomosis — has already been proven in neurosurgery, where the ELANA technique received CE marking in 2008 and FDA clearance in 2012 for intracranial bypass. Over 1,000 brain-surgery patients have been treated with it. [1] The cardiac application is the harder, larger-market spin-off.

Hype Deconstruction

Let's be clear about what this trial is not.

It is not a randomised controlled trial. SAFE-CAB II was a single-arm, prospective study. The comparison was to a historical benchmark, not to a concurrent control group of hand-sewn bypasses. That's appropriate for a first-in-human device trial — but it means the evidence, while rigorous for its stage, is not yet comparative.

It is not a minimally invasive trial. Every patient in SAFE-CAB II received a full median sternotomy. The ELANA was tested in open surgery first, which is the correct sequence — prove it works with full exposure before asking it to work through a keyhole. But the claim that this enables minimally invasive CABG is a forward-looking statement, not something this trial demonstrated.

It is not a multivessel trial. The ELANA was used only for the LITA-to-LAD connection. The other 2–3 bypasses per patient were hand-sewn. A planned multivessel investigation is in the pipeline, but it hasn't happened yet.

It is not approved. The device is investigational. No CE mark. No FDA clearance. AMT Medical is preparing both submissions, and an FDA Early Feasibility Study is in discussion with US academic centres. [1] Commercial availability is years away, not months.

The sample is small and European. 71 patients, single-centre (with one collaborating centre), Netherlands and Germany. The population was 89% male. Generalisability to broader populations — including the higher-risk patients who might benefit most from less-invasive surgery — is unknown.

None of this makes the trial bad. It makes it what it is: a well-executed Phase I/II device study that met its endpoints cleanly. The appropriate response is calibrated optimism, not a press-release rewrite.

The Deeper Architecture: Why This Approach Is Different

The ELANA technique is worth understanding because it solves a specific problem that has resisted solution for decades.

In a conventional bypass, the surgeon temporarily occludes the coronary artery with clips, makes an incision with a scalpel, and sews the graft to the artery with fine suture — typically 8–12 stitches around a 2 mm opening. The artery is not receiving blood during this time. The heart is still beating (in off-pump CABG) or arrested (in on-pump CABG). Either way, the downstream heart muscle is ischemic for the duration of the sewing.

The ELANA system works differently. A ring is first sutured to the outside of the coronary artery — a one-time attachment that doesn't penetrate the vessel. The graft vessel is then connected to this ring. A laser catheter is fed through the graft, positioned against the artery wall, and activated. A 308 nm excimer laser — the same type used in LASIK eye surgery — delivers roughly 200 pulses. The mechanism is primarily mechanical, not thermal: the laser vaporises water in the tissue, creating explosive micro-bubbles that cleanly punch a disc out of the artery wall. [7] A vacuum in the catheter holds the disc, preventing it from floating downstream. Blood flow was never interrupted.

The result is a perfectly circular opening, exactly the diameter of the laser ring, every time. No surgeon-dependent stitch tension. No variable incision shape. No ischemic time.

The six steps are: (1) attach ring to artery, (2) connect graft to ring, (3) insert laser catheter, (4) activate vacuum, (5) fire laser, (6) remove catheter with arterial disc. [2]

Twenty minutes. Standardised.

Stakeholder Landscape

Cardiac surgeons are the primary stakeholders. For the minority who already perform MIDCAB or robotic CABG, ELANA could make their existing technique faster and more reproducible. For the majority who don't — because the anastomosis is too difficult through a small incision — it could lower the barrier to entry. Whether that's good depends on your view of surgical volume centralisation. A technology that makes complex surgery easier could improve access. It could also dilute case volumes at centres of excellence.

Patients with coronary artery disease are the ultimate beneficiaries — but not yet, and not all of them. The trial population was elective CABG patients with an average age of 71. Emergency cases, reoperations, and patients with heavily calcified or intramyocardial LADs were excluded. The device is currently designed for the LITA-to-LAD connection only. If you need a saphenous vein graft to your right coronary artery, you're still getting hand-sewn.

Hospitals and health systems have a mixed interest. A standardised bypass connection could reduce operative time, shorten length of stay, and make outcomes less variable across surgeons. That's attractive to administrators. But the device will add per-procedure cost, and the capital investment in training and workflow redesign is non-trivial. Whether the economics work depends on volume and on whether reduced complications offset the device cost — a calculation that won't be possible until comparative trials exist.

AMT Medical is a clinical-stage company. The SAFE-CAB project received EU Horizon 2020 funding. [8] The company recently appointed a new CEO with experience taking a device through CE marking and FDA PMA approval to a Johnson & Johnson acquisition. [9] The commercial strategy is visible in the regulatory pathway: CE marking first (open and MIDCAB indications), then FDA Early Feasibility Study, then pivotal trials. The timeline is measured in years.

Stent manufacturers and interventional cardiologists are the competitive context. Coronary stenting (PCI) has been eating CABG's lunch for decades — it's less invasive, faster recovery, and continuously improving. A less-invasive CABG that approaches PCI's recovery profile while offering CABG's superior long-term patency for multi-vessel disease would shift the PCI-vs-CABG calculus. That's a big "if," but it's the strategic logic.

Cross-Layer Implications

The neurosurgery-to-cardiac technology transfer is the quiet story here. The ELANA technique was invented for brain bypass surgery, where temporarily occluding a cerebral artery risks stroke. The cardiac application is a spin-off — and it's a reminder that surgical innovation often crosses anatomical boundaries in ways that funding silos don't anticipate. The EU Horizon 2020 programme that funded SAFE-CAB was specifically designed to bridge this gap.

Training and credentialing will determine adoption more than the device itself. The history of surgical devices is littered with technically superior tools that failed because the training burden was too high or the credentialing pathway was unclear. AMT Medical has published a detailed six-step technique paper and is developing a training programme. But the real question is whether professional societies — the STS, EACTS, AATS — will incorporate ELANA certification into their guidelines, and whether hospitals will credential surgeons for it.

The regulatory pathway is a two-track story. In Europe, the EU Medical Devices Regulation (MDR) is more demanding than the previous MDD — longer review times, more clinical evidence required. In the US, the FDA's Breakthrough Device Program could accelerate the timeline if ELANA qualifies. The company is pursuing both simultaneously, which is strategically sound: dual CE+FDA approval unlocks expedited registration in 25+ reliance markets including Singapore, Australia, and Malaysia. [10]

The data gap is real and will persist. A randomised trial comparing ELANA-assisted CABG to conventional hand-sewn CABG — ideally in a minimally invasive setting — is the evidence the field needs. It will take years to enrol and years more to report. In the meantime, adoption decisions will be made on the strength of single-arm data and surgeon enthusiasm. That's not unusual in surgery — most surgical techniques have never been randomised — but it means the evidence base will be contested.

What This Means for You

If you are a patient with coronary artery disease: Nothing changes today. The ELANA system is not available outside clinical trials. If you need bypass surgery in the next 2–4 years, you will almost certainly receive hand-sewn anastomoses. What this trial does give you is a reason to ask your surgeon a specific question when the time comes: "Is minimally invasive bypass an option for me, and what would make it more widely available?" The answer will tell you whether your centre is on the adoption curve.

If you are a cardiac surgeon: The companion technique paper in JOVS [2] is worth reading. The six-step procedure is described in detail. The learning curve for the open technique appears manageable — the 20-minute anastomosis time in the case report is competitive with hand-sewing. The minimally invasive application is the real prize, and it hasn't been demonstrated yet. If your centre is considering a robotic CABG programme, ELANA is a technology to track, not a reason to delay.

If you are a hospital administrator or health-system planner: The cost-effectiveness case doesn't exist yet. What exists is a proof of principle that the hardest step in bypass surgery can be standardised. If the technology delivers on its promise, the value proposition is reduced length of stay, fewer sternal wound complications, and potentially broader patient access to surgical revascularisation. The risk is investing in a technology that remains niche. Watch for the CE marking decision and the first minimally invasive trial results.

If you are an investor or analyst: AMT Medical is private and clinical-stage. The SAFE-CAB II results de-risk the core technology but don't de-risk the commercial pathway. The key milestones are CE marking submission, FDA IDE approval, and the first MIDCAB clinical data. The comparator set is instructive: C-Port (the device used as the non-inferiority benchmark) was acquired by Cardica, which was later acquired by AesDex. Sutureless anastomosis devices have a 20-year history of promising early data followed by commercial disappointment. ELANA's neurosurgery pedigree and the latest-generation catheter's 97.5% patency rate are the differentiators. Whether they're enough is an open question.

Uncertainty Ledger

Bottom Line

A Dutch team has proven, in a rigorous prospective trial, that you can connect a bypass graft to a coronary artery with a laser instead of a needle and thread — and the connection stays open at rates that match the best hand-sewn surgery. The trial was small, open-chest, and single-arm. It doesn't prove the technology enables minimally invasive bypass. It proves the core mechanism works in human hearts. That's the foundation. Everything else — the keyhole surgery, the multivessel application, the regulatory approvals, the commercial trajectory — is still ahead. The appropriate posture is calibrated optimism: this is the most credible sutureless anastomosis data the field has seen in two decades, and it arrives at a moment when robotic surgery platforms are finally proliferating. The two trends are converging. Whether they converge fast enough to matter for patients in this decade is the question the next trial needs to answer.

Sources:

1. Beukers SHQ, Jacobs S, Klein P, Bronkers G, Moormans LR, Ten Berg J, Falk V, van Putte BP. The first prospective Safety And eFfectiveness trial of the ELANA heart bypass system in Coronary Artery Bypass grafting (SAFE-CAB II trial). J Thorac Cardiovasc Surg. 2026. [Tier 1 — peer-reviewed journal]
2. Beukers SHQ, et al. The ELANA Heart Bypass System: a sutureless, laser-assisted technique for coronary artery bypass anastomosis. J Vis Surg. 2026;12:2. [Tier 1 — peer-reviewed journal]
3. Global Coronary Artery Bypass Grafts Market Size & Forecast. Market Growth Reports. 2026. [Tier 3 — market research; ~365,000 procedures estimate]
4. Congruence Market Insights. Coronary Artery Bypass Graft Market Report. 2026. [Tier 3 — market research; ~800,000 procedures estimate]
5. Davierwala PM, et al. Minimally invasive coronary artery surgery: Robotic and MIDCAB. JTCVS Techniques. 2021. [Tier 1 — peer-reviewed review]
6. Ruel M, et al. Minimally invasive approaches to CABG. Eur J Cardiothorac Surg. 2026. [Tier 1 — peer-reviewed review]
7. van Doormaal TPC, et al. Vessel wall perforation mechanism of the ELANA technique. Lasers Surg Med. 2016. [Tier 1 — peer-reviewed]
8. CORDIS. Laser-Assisted Surgical System to Revolutionize Cardiac Bypass Surgeries (SAFE-CAB). EU Horizon 2020. [Tier 1 — official EU documentation]
9. AMT Medical. Leadership transition announcement. Agility PR. May 2026. [Tier 2 — company press release]
10. Med Device Guide. CE + FDA Approval Strategy. April 2026. [Tier 3 — industry analysis]